

Clinical Trials Summary for out of hours Important Reference

Acronym study title	Sunrise 4
Study Details	A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy
Principal Investigator PI Sub PI's	Proff Birtle Dr Charnley Dr Parikh
Research Nurse Team	Amanda Cook
Drug therapy	Intravenous Cetrelimab 3 weekly for 4 cycles with or without intravesical TAR 200 (gemcitabine). No dose reductions allowed.
In the event that a patient calls this hotline for advise	Please treat as per clinical protocols and inform the clinical and research teams.